Projects
Synthesis and (pre)clinical evaluation of PET radioligands for in vivo visualization of phosphodiesterase 10, an enzyme involved in neurological and psychiatric disorders. KU Leuven
Interaction between muscle mechanics and reflex hyperactivity in CP: from animal experiments to model-based diagnosis of joint hyper-resistance KU Leuven
Xenotransplantation of iPSC-derived microglia to elucidate the impact of C9orf72 hexanucleotide repeat expansion on neuroinflammation and neurodegeneration. University of Antwerp
Sabbatical Céline Gillebert: Neuropsychological rehabilitation in patients with mild cognitive impairment KU Leuven
Attentional impairments in neurological populations have long been treated as being less critical than physical impairments, and a patient’s need for care packages is still heavily informed by physical needs alone. This stems from a medical emphasis on physical recovery, but equally there is a substantial lack of knowledge about the impact of cognitive impairments on daily functioning and there is no good evidence for linking cognitive ...
Designing cell-type specific enhancers for CNS Gene Therapies. University of Antwerp
Investigation of functional immune cell-astrocyte interaction and its contribution to Neuroinflammation KU Leuven
Neurological function and dysfunction are controlled by complex biological responses involving the coordinated activities of multiple cell types in the central nervous system (CNS). A growing body of evidence points to the importance of the reciprocal communication between CNS-resident cells and the immune system for CNS physiology. Integration of the glial compartment as an active participant in neuroimmune processes is paramount. My key ...
A phloretin-based nutraceutical to promote lesion repair in multiple sclerosis. Hasselt University
Identifying novel insights into molecular pathways that contribute to axonal loss in progressive multiple sclerosis. KU Leuven
Multiple sclerosis (MS) cannot be cured and with >11 classes of disease-modifying treatments, one of the biggest challenges in therapeutic decision-making is effective stratification of treatment in the face of an uncertain prognosis. Indeed, it is not clear why certain individuals with MS go on to develop significant disabilities, in terms of walking or cognition, while others don't. One of the biggest challenges for clinicians is ...